A complete monthly investor update framework for Biotech startups at the Series A stage. Covers every section your investors expect, in the order they want to read it.
Series A investors expect the growth engine to be identified and repeatable. Show payback period, CAC by channel, and scalability of the go-to-market motion.
Biotech investors track binary milestones. Provide detailed trial progress tables and explicitly flag any protocol amendments.
Format: [Company] Update — [Month Year] — [One-line headline metric]
Open with a 2–3 sentence executive summary. Lead with your best signal, not with pleasantries. Investors read subject lines and opening sentences to decide how much time to give the rest.
Include a simple table or bulleted list with current value, prior month value, and MoM change. Track these Biotech metrics:
Full P&L summary, ARR bridge (new + expansion - churn), gross margin, and 90-day cash forecast. Include actuals vs budget for major line items.
Wins (3–5 bullets)
Specific achievements with quantified impact. Include customer quotes when available. Celebrate team performance by name.
Challenges (1–3 bullets)
State the problem clearly, explain your current hypothesis, and describe what you are doing differently. Investors trust founders who communicate risk early.
New hires (name, role, start date), open roles, and any departures (handled with care). Include a brief note on team health and culture if something notable happened.
Limit to 2–3 specific, actionable asks. Examples for Series A stage:
Three numbered priorities with an owner and success metric for each. This closes the update and sets the baseline for next month's wins section. Never list more than three — prioritization is itself a signal.
Full P&L summary, ARR bridge (new + expansion - churn), gross margin, and 90-day cash forecast. Include actuals vs budget for major line items.
Always Include
Include When Available
A Series A Biotech investor update should cover: KPI dashboard with Clinical Trial Enrollment (vs plan), Cash Runway at Current Burn, IND / NDA Milestone Status, a financial summary showing burn rate and runway, product milestones from the prior month, a team update section, and 2–3 specific asks. Series A investors expect the growth engine to be identified and repeatable. Show payback period, CAC by channel, and scalability of the go-to-market motion.
600–900 words. Series A boards read every word. Investors read updates between meetings and board calls. Longer does not mean more informative — it means more time asking for their attention.
Biotech investors track: Clinical Trial Enrollment (vs plan), Cash Runway at Current Burn, IND / NDA Milestone Status, Patent Filings and Grants, Partnership and Licensing Revenue, Regulatory Meeting Outcomes. Biotech investors track binary milestones. Provide detailed trial progress tables and explicitly flag any protocol amendments.
Monthly is the industry standard for seed through Series B. Growth-stage companies with formal boards typically move to a monthly narrative plus a quarterly formal board package. Never go more than 60 days without an update — silence is interpreted as a problem.
Make asks specific, time-bounded, and easy to fulfill. Avoid generic asks like "intro to anyone in fintech." Effective examples: Intro to [specific Fortune 500] procurement contact for enterprise pilot. Feedback on VP Engineering candidate (sharing brief). Access to limited partner network for Series B lead sourcing (12 months out). Include a direct action step for each ask.
Get the Biotech Series A investor update template as a Google Doc or Notion template. Copy, customize, and send this month.
Includes email template, KPI tracking table, and subject line swipe file